![]()  | 
![]()  | ![]()  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
    
     
    
    
 
    
    
    
I've been invested in this one for a few months and I am fairly  bullish on it. They have drugs for gastrointestinal illnesses in Phase III clinical trial. They could potentially get regulatory approval later this year in Canada and US. The main drug (Synsorb Pk) addresses a market potential of $2B. Anyone else with any info/opinions ? Salut ! Francois  | ||||||||||||||
 
        
 
  | 
    
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |